| Printable Version (pdf) |

8:30-9:00 am | Registration and Continental Breakfast

9:00-9:10 am

Joseph Wu, MD, PhD
Director, Stanford Cardiovascular Institute and Simon H. Stertzer, MD, Professor of Medicine and Radiology, Stanford School of Medicine

Steven Artandi, MD, PhD
Director, Stanford Cancer Institute and Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry, Stanford School of Medicine

9:10-9:25 am

Lloyd Minor, MD
Carl and Elizabeth Naumann Professorship for the Dean, Stanford School of Medicine

David Entwistle, MHSA
President and CEO, Stanford Health Care

Paul King, MHA
President and CEO, Stanford Lucile Packard Children's Hospital

9:25-9:55 am | "Emerging Science and Technology in Health and Medicine: A Brave New World"

Victor Dzau, MD
President, National Academy of Medicine

9:55-10:05 am | Q&A Session

10:10-10:25 am | "A Government, Academic, Private Partnership for Cancer Drug Discovery"

James Doroshow, MD
NCI Deputy Director for Clinical and Translational Research, NIH

10:25-10:40 am | "Big, Team, Open Science at the Allen Institute"

Allan Jones, PhD
President and CEO, Allen Institute

10:40-10:55 am | "Collaboration, Partnerships, and Philanthropy"

Sandy Weill
Chairman Emeritus and Former CEO, Citigroup

10:55-11:10 am | "CIRM: How California’s Investment is Delivering Something Better than Hope"

Maria Millan, MD
President and CEO, California Institute for Regenerative Medicine

11:10-11:30 am | Panel Discussion

11:30-1:00 pm | Networking Lunch and Poster Viewing

1:00-1:15 pm | "Pre-Print Servers, Data Sharing, and Drug Trials"

Howard Bauchner, MD
Editor-in-Chief, JAMA

1:15-1:30 pm | "Breaching Barriers in Translational Research"

Orla Smith, PhD
Editor, Science Translational Medicine, Science (AAAS)

1:30-1:40 pm | Panel Discussion

1:40-2:10 pm

Marc Tessier-Lavigne, PhD, FRS, FRSC
President and Bing Presidential Professor, Stanford University

Lloyd Minor, MD
Carl and Elizabeth Naumann Professorship for the Dean, Stanford School of Medicine

2:10-2:30 pm | Coffee Break

2:30-2:45 pm | "Pipeline in a Pill: Multiple Indications Treated by a Single Molecule"

John Reed, MD, PhD
Executive VP and Global Head of R&D, Sanofi

2:45-3:00 pm | "Enabling Precision Medicine: Views from an Industry Perspective"

Alan Sachs, MD, PhD
CSO, Thermo Fisher

3:00-3:15 pm | "Mission-Oriented R&D: Using Heart, Science & Ingenuity, Create Transformational Medicine to Improve the Health of Humanity"

Mathai Mammen, MD, PhD
Global Head of R&D at Janssen Pharmaceutical Company of Johnson & Johnson

3:15-3:30 pm | "Takeda’s R&D Transformation: The Rebirth of a 238-Year-Old Healthcare Institution"

Andrew Plump, MD, PhD
Chief Medical and Scientific Officer, Takeda

3:30-3:45 pm | "Opportunities for Advancing R&D: Insights from Human Data"

Sandra Horning, MD
Head of Global Project Development and CMO, Genentech

3:45-4:10 pm | Panel Discussion

4:15-4:20 pm | Introduction of John Martin, PhD

Paul Berg, PhD
Robert W. and Vivian K. Cahill Professor of Cancer Research, Emeritus, Stanford University School of Medicine | Nobel Prize 1980

4:20-4:40 pm | Awardee Lecture

John C. Martin, PhD
Former CEO, Gilead Sciences

4:45-5:45 pm | Poster Viewing & Wine and Cheese Reception

| Printable Version (pdf) |

8:00-8:45 am | Registration and Continental Breakfast

8:45-9:15 am | "How Exosomes are Made and Selectively Capture Small RNAs for Secretion from Human Cells"

Randy Schekman, PhD
HHMI Investigator and Professor, UC Berkley | Nobel Prize 2013

9:15-9:25 am | Q&A Session

9:25-9:45am | "Accelerating Progress in Translational Cancer Research Through Data Integration"

Brian Druker, MD
Jeld-Wen Chair of Leukemia Research and Director, Knight Cancer Institute, Oregon Health Science University

9:45-9:55 am | Q&A Session

10:00-10:15 am

George Yancopoulos, MD, PhD
President and CSO, Regeneron Pharmaceuticals, Inc.

10:15-10:30 am | "Exploring Immunotherapy in Immune Diseases and Beyond"

Jeffrey Bluestone, PhD
CEO and President, Parker Institute for Cancer Immunotherapy

10:30-10:45 am | "Engineering T Cells for Cancer Therapy"

Crystal Mackall, MD
Director, Stanford Center for Cell Therapy and Parker Institute for Cancer Immunotherapy

10:40-11:05 am | Panel Discussion

11:05-11:25 am | Coffee Break

11:25-11:35 am | "Next-Generation Gene Editing for Allogeneic Immune Cell Therapeutics"

Steven Kanner, PhD
CSO, Caribou Biosciences

11:35-11:45 am | "Small Trials Showing Large Differences – New Paradigms in Cancer"

Sanjeev Redkar, PhD, MBA
President, Apollomics

11:45-11:55 am | "Targeting Myeloid Cells for Cancer Immunotherapy"

Charlene Liao, PhD
President and CEO, Immune-Onc Therapeutics

11:55-12:05 pm | "VCs Encouraging Exploring?"

Camille Samuels, MBA
Partner, Venrock

12:05-12:45 pm | Panel Discussion

Anthony Adamis, MD | Senior VP of Development and Innovation, Genentech
Charlene Liao, PhD | President and CEO, Immune-Onc Therapeutics
Woodrow Myers, Jr., MD, MBA | Managing Director, Myers  Ventures, LLC
Ram Shriram | Founder, Sherpalo Ventures
Camille Samuels, MBA | Partner, Venrock
Steven Kanner, PhD | CSO, Caribou Biosciences
Sanjeev Redkar, PhD, MBA | President, Apollomics

12:45-2:15 pm | Networking Lunch and Poster Viewing

2:15-2:45 pm

Young Sohn
President and CSO, Samsung Electronics
Chairman of the Board, Harman

2:45-2:55 pm | Q&A Session

2:55-3:15 pm | "Future in Health: Drugs, Devices, and Data"

Peter Fitzgerald, MD, PhD
Professor Emeritus, Medicine and Engineering, and Director, Center for CV Innovation, Stanford School of Medicine | Founder, Triventures

3:15-3:20 pm | Q&A Session

3:25-3:40 pm | "Advancing the Development of Advanced Therapy Medicinal Products"

Peter Marks, MD, PhD
Director, Center for Biologics Evaluation and Research, US Food and Drug Administration

3:40-3:55 pm | "Mismatch between Need and Investment in Chronic Disease Drug Development"

Robert Califf, MD
Former FDA Commissioner | Professor of Cardiology, Duke University

3:55-4:15 pm | Q&A Session

4:15-4:20 pm | Closing Remarks

4:20-5:30 pm | Poster Viewing & Wine and Cheese Reception